TRISALUS LIFE SCIENCES INC

TLSINASDAQ

🏆 #2563 by market capEarnings Nov 16US Equity

$5.74▲ $0.16 (+2.87%)

🌙 After hours$5.63▼ 1.92%Regular close · extended-hours price shown

1h—

24h▲ 2.9%

7d▲ 24.0%

14d▲ 31.1%

30d▲ 35.4%

1y▲ 59.0%

🏦Market Cap

$353M

Small Cap

📈Revenue Growth (YoY)

+39.6%

High Growth

📊Gross Margin

85.1%

High

💵FCF Margin

—

⚖️P/S Ratio

7.7x

Fair

Otter Score

Weak

Trading Snapshot

Day Range: $5.69 – $5.81
52-Week Range: $2.20 – $7.95
Volume: $3.82B
Avg Volume: $3.02B
Shares Outstanding: 61.4M
Next Earnings: Oct 3, 2026

Fundamentals Snapshot

Annual Revenue: $45M
Last Q Revenue: $11M
P/E Ratio: —
P/S Ratio: 7.7x
EPS (TTM): $-0.68
Dividend Yield: —

Why Investors Own TLSI

✓High-growth profile — revenue up +36.4% YoY with expanding US Equity exposure.
✓Healthy economics — 26% gross margin and 22% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$45M▲ +34.4% YoY

Gross Margin (TTM)

25.7%▲ +3.0% YoY

Operating Income (TTM)

$10M▲ +34.4% YoY

Free Cash Flow (TTM)

$10M▲ +34.4% YoY

About TRISALUS LIFE SCIENCES INC

TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.

🦦